Although fidaxomicin vs vancomycin is associated with better sustained clinical response and lower Clostridioides difficile infection (CDI) recurrence, most patients with CDI are not receiving ...

Fidaxomicin was superior to vancomycin in patients with Clostridioides difficile infection, resulting in reduced risk for treatment failure and relapse. Among patients with Clostridioides difficile ...

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "DIFICID Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides a detailed picture ...

Cao X, Boyaci H, Chen J, Bao Y, Landick R, Campbell E. Basis of narrow-spectrum activity of fidaxomicin on Clostridioides difficile. Nature . Published online April 6, 2022. doi: 10.1038/s41586 ...

The antibiotic fidaxomicin acts selectively on the bacterium Clostridioides difficile, a main cause of intestinal infections. Structural and biochemical experiments reveal a region in the enzyme ...

I’ll lead with Dr Gerding on this one. We have new data, or at least a growing literature around fidaxomicin [Dificid] vs vancomycin [Vancocin]. I believe that was addressed in the IDSA ...

U.S. Food and Drug Administration (FDA) has approved fidaxomicin for C. difficile-associated diarrhea in pediatric patients. Food and Drug Administration (FDA) approved a New Drug Application (NDA) ...